Q4 FY21 (JAN-MAR 2021) Concall Summary

ALKYL AMINES CHEMICALS LIMITED

Concall Date: 28 May 2021

Revenue: ₹382.1 cr (▲62.7%) Net Profit: ₹92.6 cr (▲88.2%)

FINANCIAL HIGHLIGHTS
PARTICULARS Q4 FY21 Q4 FY20 Change % FY21 FY20 Change %
(₹ cr) (₹ cr) YoY (₹ cr) (₹ cr) YoY
Revenue from Operations 382 235 62.7% 1,242 993 25.1%
Net Profit 93 49 88.2% 295 215 37.2%
Final Dividend ₹6/share (FY21)

• The earnings per share (EPS) (diluted) stood at ₹45.24 and ₹144.3 for Q4 FY21 and FY21, respectively.

BUSINESS HIGHLIGHTS
• In FY21, the revenue from domestic business and exports was ₹1,016.6 crore and ₹225.8 crore,
respectively.
• The life science segment contributed ~75% towards revenue, of which the pharma sector contributed
55% and agrochemicals contributed 45%.
• In FY21, the capital expenditure (capex) was in the range of ₹140 crore to ₹150 crore.
• During FY21, it faced supply chain issues on account of the ongoing pandemic. Additionally, there was
a price hike for most of its raw materials.
• Existing customers contributed ~95% of revenue towards its business.

UPDATES
• Due to the ongoing pandemic, the commissioning of their new acetonitrile plant in Dahej has been
delayed. However, it expects to commission it in H2 FY22. Therefore, the revenue would be recognized
form H2 FY22.
• In FY21, it completed the expansion of the methylamine plant, and the capacity of the same is ~150
tonnes per day.

FUTURE OUTLOOK
• The volume growth is anticipated to be in the range of 10%-15% in the next 3 to 5 years.
• Its new aliphatic mine plant in Kurkumbh is anticipated to be completed in H2 FY23. The capex for
the same would be ~₹300-₹350 crore. This would expand their aliphatic amine portfolio by ~30%.
• In FY23, it is looking forward to acquire a new land (50-100 acres) for further expansion.
 Concall Summary
ALKYL AMINES CHEMICALS LIMITED

• In the future, the margin of speciality chemicals is anticipated to remain in the same range. However,
due to the increase in the price of acetic acid, the margins might be affected.
• The capex for FY22 is anticipated to be ~₹200 crore. The capex for FY23 would be in the same range.

SEBI Registration no: IHN3000007493

Disclaimer:

This document has been prepared to provide a brief summary of the conference call conducted by the companies and
is intended to be used for learning enhancements. Nothing contained herein should be construed as a
recommendation on any stock or sector.